1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. FUSN PHAR
  6. News
  7. Summary
    FUSN   CA36118A1003

FUSN PHAR

(FUSN)
  Report
Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
2.040 USD   -6.85%
02:16pWedbush Lowers Price Target for Fusion Pharmaceuticals to $12 From $19, Maintains Outperform Rating
MT
09:56aFUSN PHAR : Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Program Updates - Form 8-K
PU
08:04aFUSION PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

FUSION PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)

06/21/2022 | 07:36am EDT

Item 5.07. Submission of Matters to a Vote of Security Holders.

Fusion Pharmaceuticals Inc. (the "Company") held its annual meeting of shareholders on June 14, 2022 (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted in the following manner with respect to the following proposals:


    1.   The election of Directors, each to serve until the 2023 annual meeting of
         shareholders. The final voting results were as follows:



Nominee                             For           Against        Abstain
Donald Bergstrom, M.D., Ph.D.     26,898,848             0           8,390
Pablo Cagnoni, M.D.               26,890,723             0          16,515
Johan Christenson, Ph.D.          26,898,798             0           8,440
Barbara Duncan                    23,778,571             0       3,128,667
Steve Gannon                      26,898,783             0           8,455
Chau Khuong                       26,870,584             0          36,654
Philina Lee, Ph.D.                26,898,982             0           8,256
Heather Preston, M.D.             23,766,724             0       3,140,514
John Valliant, Ph.D.              26,898,848             0           8,390



    2.   The ratification of the appointment of PricewaterhouseCoopers LLP as the
         Company's independent registered public accounting firm the current
         fiscal year ending December 31, 2022 was approved as follows:



For:         27,628,417
Against:              0
Abstain:          7,232


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about FUSN PHAR
02:16pWedbush Lowers Price Target for Fusion Pharmaceuticals to $12 From $19, Maintains Outpe..
MT
09:56aFUSN PHAR : Fusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Cli..
PU
08:04aFUSION PHARMACEUTICALS INC. Management's Discussion and Analysis of Financial Conditio..
AQ
07:01aFusion Pharmaceuticals Announces Second Quarter 2022 Financial Results and Clinical Pro..
PR
08/02Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
07/07Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
07/06Fusion Pharmaceuticals Shares Rise After William Blair Starts Coverage at Outperform
MT
07/06William Blair Initiates Coverage on Fusion Pharmaceuticals With Outperform Rating
MT
06/23SECTOR UPDATE : Health Care Stocks Lead Thursday Markets Recovery
MT
06/23SECTOR UPDATE : Health Care Stocks Again Outpacing Other Sectors to the Upside
MT
More news
Analyst Recommendations on FUSN PHAR
More recommendations